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Aims Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxi-
city. Children are particularly sensitive toDOX-induced heart failure.Here, the impact of p53 inhibition on acute vs. late-
stage DOX cardiotoxicity was examined in a juvenile model.
Methods and
results
Two-week-old MHC-CB7 mice (which express dominant-interfering p53 in cardiomyocytes) and their non-transgenic
(NON-TXG) littermates received weekly DOX injections for 5 weeks (25 mg/kg cumulative dose). Oneweek after the
last DOX treatment (acute stage), MHC-CB7mice exhibited improved cardiac function and lower levels of cardiomyo-
cyte apoptosis when compared with the NON-TXGmice. Surprisingly, by 13 weeks following the last DOX treatment
(late stage), MHC-CB7 exhibited a progressive decrease in cardiac function and higher rates of cardiomyocyte apoptosis
when compared with NON-TXGmice. p53 inhibition blocked transient DOX-induced STAT3 activation in MHC-CB7
mice, which was associated with enhanced induction of the DNA repair proteins Ku70 and Ku80. Mice with cardiomyo-
cyte-restricted deletion of STAT3 exhibited worse cardiac function, higher levels of cardiomyocyte apoptosis, and a
greater induction of Ku70 and Ku80 in response to DOX treatment during the acute stage when compared with
control animals.
Conclusion These data support a model wherein a p53-dependent cardioprotective pathway, mediated via STAT3 activation, miti-
gates DOX-induced myocardial stress during drug delivery. Furthermore, these data suggest an explanation as to how
p53 inhibition can result in cardioprotection during drug treatment and, paradoxically, enhanced cardiotoxicity long
after the cessation of drug treatment.
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1. Introduction
Anthracyclines, as exemplified by doxorubicin (DOX), are widely used
anti-cancer chemotherapeutics. Although highly efficacious, anthracy-
clines are also cardiotoxic. Anthracycline-induced cardiotoxicity can be
observed during drug delivery (acute stage) as well as years after the ter-
mination of drug treatment (late stage). Acute stage cardiotoxicity is
characterized by hypotension, tachycardia, arrhythmia, and transient
depression of left ventricular function.1–4 Late-stage anthracycline
cardiotoxicity is characterized by recalcitrant heart failure, the severity
of which is directly related to cumulative drug exposure. Children are
particularly sensitive to anthracycline-induced cardiotoxicity.5,6
It is generally thought that free radical-induced damage contributes to
anthracycline-inducedcardiotoxicity.7However,numerousothercellular
changes have been noted, including DNA damage, inhibition of protein
synthesis, myofibre degeneration, transcriptional inhibition of myogenic
programmes, and cardiomyocyte apoptosis.8–10 It has recently been
reported that cardiomyocyte-restricted deletion of topoisomerase-II b
(Top2b) reduced DOX-induced cardiotoxicity in mice.11 Interestingly,
in the absence of Top2b, DOX-induced DNA damage was reduced,
with a concomitant reduction in p53 induction. Despite progress in iden-
tifyingcellularpathwaysperturbedbyanthracyclines, it hasproveddifficult
to determine theprecisemolecular aetiologieswhich give rise to acute vs.
late-stage cardiotoxicity.
Many studies examining anthracycline cardiotoxicity utilized a limited
number of high-dose DOX injections with terminal analyses shortly
after the onset of treatment. Although such high-dose/short-duration
studies provide insight into the mechanism of immediate drug toxicity,
the clinical use of DOX entails the administration of multiple lower
doses over an extended period of time, and the most challenging
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pathophysiological outcome is the recalcitrant heart failure that can
occur long after the termination of treatment. Accordingly, several
groups have developed long-term rodent models in an effort to better
mimic the clinical problem.12–15 These studies have suggested that
unique molecular mechanisms can contribute to acute vs. late-stage
DOX cardiotoxicity.
It is well established, using high-dose/short-duration studies, that
DOX treatment induces transient expression of the tumour suppressor
p53, and furthermore that pharmacologic or genetic inhibitionof p53 ac-
tivity reduces DOX-induced cardiomyocyte apoptosis with a concomi-
tant improvement in cardiac function.15–17 In this study, MHC-CB7
transgenicmice (which express dominant-interfering p53 in cardiomyo-
cytes)18 were employed to examine the impact of p53 inhibition on
acute vs. late-stage DOX-induced cardiotoxicity using a juvenile
mouse model of chronic DOX-induced cardiac dysfunction. Although
inhibition of p53 activity was protective during acute cardiotoxicity, a
progressive reduction in systolic function, and comparatively higher
rates of cardiomyocyte apoptosis, were observed during late-stage
DOXcardiotoxicity inMHC-CB7micewhen comparedwith their non-
transgenic littermates.Molecular analyses revealed a transient induction
of STAT3 activity in DOX-treated NON-TXG mice, but not in DOX-
treated MHC-CB7 mice. A potential mechanisms as to how p53 inhib-
ition can promote cardioprotection during drug treatment and, para-




This study utilized MHC-CB7 mice18 (n ¼ 72), and their non-transgenic lit-
termates (n ¼ 70). The MHC-CB7 transgene utilizes the cardiomyocyte-
restricted alpha-cardiac myosin heavy chain promoter19 to target expres-
sion of the p53CB7 allele, which harbours an arginine to proline substitution
at amino acid residue #193 that results in a dominant-interfering phenotype
by blocking p53-dependent transcription.20,21 Mice were maintained in a
DBA/2J genetic background. Mice with cardiac-restricted STAT3 deletion
(STAT3-CKO)22 were also utilized (n ¼ 16 STAT3-CKOmice and 17 wild-
type controls). These animals (maintained in aC57Bl/6J genetic background)
carried a modified STAT3 allele wherein loxP sites were inserted between
exons 17 and 18 and between exons 20 and 21.22 These animals also
carried a transgene encoding Cre recombinase under the transcriptional
regulation of the myosin heavy chain promoter23 to drive cardiomyocyte-
restricted STAT3 deletion. The wild-type controls lacked the Cre-encoding
transgene, and were either heterozygous or homozygous for the floxed
STAT3 allele. Numbers of mice used to generate each dataset are indicated
in Supplementary material online, Tables S1–S4.
2.2 DOX cardiotoxicity model
A juvenilemodel featuring aspects of acute and chronicDOX cardiotoxicity
was employed.15 Mice received a total of 25 mg/kg of DOX (five intra-
peritoneal injections of 5 mg/kg in saline, given at 1 week intervals beginning
at 2 weeks of age, Sigma, St Louis, MO, USA; control mice received saline
injections). To avoid local tissue damage, a different region of the peritoneal
cavity was injected at each time point, and no overt inflammation or damage
was apparent at the injection sites.One cohort ofmicewas sacrificed1week
after the final DOX injection (acute stage). A second cohort was sacrificed
13 weeks after the final DOX injection (late stage). Mice were sacrificed
via cervical dislocation under isofluorane anaesthesia (1.5%), and hearts
were immediately harvested. All animal protocols were approved by the
Indiana University School of Medicine Institutional Animal Care and Use
Committee.
2.3 Echocardiography
Mice were lightly anaesthetized with 1.5% isofluorane until their heart rate
stabilized at 400–500 bpm. Two-dimensional images were obtained using
a high-resolution Micro-Ultrasound system (Vevo 770, VisualSonics Inc.,
Toronto, Canada) equipped with a 40-MHz mechanical scan probe. Frac-
tional shortening (FS, calculated from short-axis images) and ejection frac-
tion (EF, calculated from parasternal long axis images) were calculated
using the Vevo Analysis software (version 2.2.3) as described previously.24
2.4 Western blot analysis
Proteins were extracted and quantitated using the Coomassie Blue method
(Pierce, Rockford, IL, USA) as described previously.18 Samples were solubi-
lized in sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE) loading buffer for 5 min at 958C and resolved on 7 or 10% SDS–
PAGE gels.25 Fractionated proteins were then electro-transferred from
the gel to nitrocellulose (Amersham)filters inTowbin buffer at 200-mAcon-
stant current and analysed by western blotting as described.26 The filters
were stained with 0.1% naphthol blue–black in 45% methanol, 10% acetic
acid to assess the efficiency of transfer. Antibodies used recognized p53
(#PC-35, EMDChemicals,Gibbstown,NJ,USA), PARP1 (#9542,Cell Signal-
ing Technology, Danvers, MA, USA), Actin (#sc-1616-R, Santa Cruz Bio-
technology), P-STAT3[Tyr705] (#9145S, Cell Signaling Technology), total
STAT3 (#9139S, Cell Signaling Technology), Ku70 (#sc-365766, Santa
Cruz Biotechnology), and Ku80 (#2180S, Cell Signaling Technology).
Signal was visualized by the ECL method according to the manufacturer’s
protocol (Amersham). Western signal was digitized and quantitated using
ImageJ software.
2.5 Histology
Hearts were harvested, cryoprotected in 30% sucrose, embedded and sec-
tioned at 10 mm using standard techniques.27,28 To quantitate cardiomyo-
cyte apoptosis, four transverse sections from each heart, sampled from
themidpoint between the apex and base, were post-fixed in 4% paraformal-
dehyde and screened for anti-activated caspase-3 immune reactivity (anti-
body #G7481, Promega, Madison, WI, USA), followed by a horseradish
peroxidase-conjugated secondary antibody; signal was visualized with a dia-
minobenzidine reaction, as described previously.18 TUNEL analyses were
performed on adjacent sections using the ApopTag Apoptosis Detection
kit according to the manufacturer’s protocol (Chemicon International, Bill-
erica, MA, USA).
2.6 Statistic analysis
All values are presented as mean+ SEM. Statistical significance was deter-
mined by Student’s t-test (for two group comparison for quantification of
western blot signals for p-STAT3/STAT3 a- and b-subunits) or two-way
ANOVA (Holm–Sidak method) for multi-group comparison. P, 0.05
was considered significant.
3. Results
3.1 Inhibition of p53 activity does not prevent
late-stage DOX-induced cardiac dysfunction
in a juvenile cardiotoxicity model
We have previously shown, using a chronic juvenile mouse model, that
DOX treatment results in low levels of cardiomyocyte apoptosis during
drug delivery, but comparatively higher levels of apoptosis long after
drug withdrawal.15 To elucidate the role of p53 in this process,
14-day-old MHC-CB7 mice and their NON-TXG littermates were
given weekly DOX injections for a total of 5 weeks. One week after
the last injection, half of the animals were sacrificed and their hearts
were harvested for cell and molecular analyses (acute stage). The
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remaining animals were allowed to recover in the absence of DOX for
an additional 12 weeks prior to sacrifice (late stage). Echocardiography
was performed to monitor cardiac function throughout the study. In
agreement with previous findings,15 both FS (Figure 1) and EF (see Sup-
plementary material online, Table S1) progressively deteriorated in
DOX-treated NON-TXG juvenile mice during the acute stage when
compared with the saline-treated NON-TXG controls, and remained
stable albeit at a suppressed level throughout the late stage. In contrast,
DOX had little impact on FS and EF in MHC-CB7 mice during the acute
stage, consistent with a cardioprotective role for p53 inhibition. However,
systolic function deteriorated in the DOX-treated MHC-CB7 mice during
the late stage (Figure 1 and Supplementary material online, Table S1).
3.2 Inhibition of p53 results in higher levels
of late-stage DOX-induced cardiomyocyte
apoptosis
Activated caspase-3 immune reactivity was used to quantitate cardio-
myocyte apoptosis. Since activated caspase-3 immune reactivity is
present in the cytoplasm, cardiomyocytes at early stages of apoptosis
can be identified based on cell size and shape (Figure 2A).18 In agreement
with previous results,15 cardiomyocyte-activated caspase-3 immune re-
activity was induced in hearts from DOX-treated NON-TXG juvenile
mice during acute toxicity, and the level was approximately four-fold
higher during the late stage (Figure 2B). There was no induction of
cardiomyocyte-activated caspase-3 immune reactivity during the
acute stage in DOX-treated MHC-CB7 juvenile mice when compared
with saline-treated animals, again supporting the notion that p53
inhibition can be cardioprotective. Surprisingly, a very high level of
cardiomyocyte-activated caspase-3 immune reactivity was present in
late-stage MHC-CB7 hearts, exceeding that seen in the late-stage
NON-TXG mice (Figure 2B). Similar results were obtained using
TUNELanalysis, with.2-foldmoreTUNEL-positive nuclei in late-stage
DOX-treated MHC-CB7 hearts when comparedwith late-stage DOX-
treatedNON-TXGhearts (seeSupplementarymaterial online,Table S2,
for the cardiac attributes for these animals).
PARP1 is a caspase-3 substrate, and accumulation of cleaved PARP
provides another marker for apoptosis.29 Western blots revealed the
Figure 1 Cardiac function in saline- and DOX-treated juvenile mice in the acute and late stages. (A) FS in saline- and DOX-treated NON-TXG and
MHC-CB7 mice in the acute and late stages. X-axis indicates the age of the mice at analysis; vertical arrows indicate the age at DOX injection.
*P, 0.05 for DOX-treated NON-TXG vs. saline-treated NON-TXG mice, †P, 0.05 for DOX-treated NON-TXG vs. DOX-treated MHC-CB7
mice, ‡P, 0.05 for DOX-treated MHC-CB7 vs. saline-treated MHC-CB7 mice. (B) Representative short-axis echocardiograms from saline- and DOX-
treated NON-TXG and MHC-CB7 mice in the acute and late stages.
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presence of cleaved PARP1 in hearts from DOX-treated NON-TXG
mice, but not in NON-TXG saline-treated controls, during the acute
stage (Figure 2C). Even higher levels of cleaved PARP1 were observed
in DOX-treated NON-TXG hearts during the late stage, in agreement
with the observed increase in activated caspase-3 immune reactivity and
TUNEL signal (above). No cleaved PARP1 was detected in hearts from
acute-stage DOX-treated MHC-CB7 mice, but very high levels were
present in late-stage hearts (exceeding those seen in the late-stage
NON-TXG hearts, Figure 2C). Western blot analyses demonstrated
transient induction of endogenous p53 in response to DOX treatment
(Figure 2D). The observation that p53 inhibition blocks acute stage apop-
tosis, but potentiates late-stageapoptosis, indicates a fundamental differ-
ence in the underlying mechanisms of DOX-induced cardiomyocyte
death at these two stages.
3.3 Inhibition of p53 activity blocks STAT3
activation during DOX treatment
The presence of higher levels of cardiomyocyte apoptosis in MHC-CB7
vs. NON-TXG mice during late-stage DOX cardiotoxicity was
Figure 2 Cardiomyocyte apoptosis in saline- and DOX-treated NON-TXG and MHC-CB7 mice in the acute and late stages. (A) Representative acti-
vated caspase-3 immune reactive cardiomyocyte from aDOX-treatedMHC-CB7mouse (bar ¼ 50 mm). (B) Quantitation of activated caspase-3 immune
reactive cardiomyocytes (CSP-3+CM) per mm2 in hearts from saline- andDOX-treatedNON-TXG andMHC-CB7mice in the acute and late stages. (C)
Western blot analysis of cleaved PARP1 accumulation during the early and late stages inNON-TXGandMHC-CB7mice; densitometric quantitation of the
PARP1signal shown. (D) p53protein (left panel) is induced in juvenileNON-TXGhearts followingDOXtreatment (single injection, 5 mg/kg; time indicates
the number of hours post-injection when the hearts were harvested); right panel shows a GAPDHwestern blot from the same transfer to confirm equal
loading.
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somewhat surprising, and suggests thepresenceof ap53-dependent car-
dioprotective activity. Since DOX treatment results in only transient
p53 induction (Figure 2), it is likely that this cardoprotective activity
occurs during the acute stage. Indeed, such an activity has been hypothe-
sized by others.30 If true, onewould anticipate that the cardioprotective
pathway would be present during DOX treatment in NON-TXG mice
(i.e. in the acute stage and not in the late stage), andwould be completely
absent in DOX-treated MHC-CB7 mice. Western blot screens were
performed to identify such an activity. Signal Transducers andActivators
of Transcription 3 (STAT3) is a transcription factor implicated in the
regulation of adaptive growth and survival in cardiomyocytes.31–33 A
marked increase in the level of phosphorylated STAT3 at tyrosine
residue 705 (P-STAT3[tyr705]) was observed during the acute stage
in NON-TXG mice, but not in MHC-CB7 mice (Figure 3). Phosphoryl-
ation at tyrosine residue 705 facilitates STAT3 dimerization, and
consequently, pathway activation.34 P-STAT3[tyr705] levels in DOX-
treated NON-TXGmice returned to base-line in the late stage. In con-
trast, no overt changes in STAT3 phosphorylation at serine residue 727
(P-STAT3[ser727], another regulatory residue)35 was observed in
DOX-treated NON-TXG or MHC-CB7 mice (Figure 3).
3.4 STAT3 activity mitigates DOX-induced
Ku expression
Given that STAT3 is cardioprotective, onewouldanticipate thatmarkers
indicative of cardiac stress would also be differentially expressed in
NON-TXGvs.MHC-CB7DOX-treatedhearts. SinceDOXcardiotoxi-
city is thought to result at least in part from reactive oxygen
species-induced stress, and since reactive oxygen species are known
to damage DNA, western blot screens for changes in the expression
Figure3 p53 inhibitionblocks transient,DOX-inducedP-STAT3[tyr705] phosphorylation in the acute stage, andenhancesKu70 andKu80expression in
the acute and late stages.Densitometric quantitation of thewestern blot signals is shown.Note that the STAT3-b isoform lacks the serine 727 residue, and
hence is not detected in the anti-P-STAT3[ser727] immune blot.
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dimer protein complex comprising Ku70 and Ku80) is induced in re-
sponse to DNA damage; Ku binds to double-stranded DNA breaks
and facilitates non-homologous end joining.36 Interestingly, it has also
been suggested that Ku70 functions as a transcriptional co-factor in re-
sponse to oxidative stress.37,38 DOX treatment resulted in an induction
of Ku70 and Ku80 inNON-TXGmice during the acute stage; the induc-
tion of Ku70 and Ku80 was even greater in MHC-CB7 hearts. Ku70 and
Ku80 expression remained elevated in late-stage DOX-treated
NON-TXG hearts; once again, levels were higher in the DOX-treated
MHC-CB7 hearts (Figure 3).
To directly evaluate whether STAT3 activity mitigates DOX-induced
Ku expression, mice with cardiomyocyte-restricted deletion of STAT3
(STAT3-CKO) and their wild-type (WT) controls were given weekly
DOX injections for a total of 5weeks, and 1week after the last injection,
the animals were sacrificed and their hearts were harvested for cell and
molecular analyses. Cardiac function was monitored over the course of
the experiment. DOX treatment resulted in a rapid decrease in cardiac
function (FS and EF) in theWTmice during the acute stage (Figure 4A and
B). The impact of DOX treatment on cardiac function was even more
pronounced in the STAT3-CKOmice. Activated caspase-3 immune re-
activity revealed an increased level of cardiomyocyte-activated
caspase-3 immune reactivity in STAT3-CKO hearts when compared
with WT hearts (Figure 4C). Similar results were obtained using
TUNEL analysis, with .2-fold more TUNEL-positive nuclei in DOX-
treated STAT3-CKO hearts when compared with DOX-treated WT
hearts (seeSupplementarymaterial online,Table S4, for the cardiac attri-
butes of these animals). The level of cleavedPARP1was greater in acute-
stage STAT3-CKOheartswhen comparedwithWThearts, further sup-
porting higher rates of cardiomyocyte apoptosis in these animals
(Figure 5). Western blot analysis also revealed that DOX treatment
resulted in enhanced induction of Ku70 and Ku80 in STAT3-CKO
hearts when compared with WT hearts (Figure 5). Collectively, these
data demonstrate that the loss of STAT3 renders theheartmore suscep-
tible to DOX-induced stress, and that STAT3 activity mitigates DOX-
induced Ku expression.
4. Discussion
The data presented here, utilizing juvenile mice with cardiomyocyte-
restricted expression of a dominant-interfering p53 variant, demon-
strated that p53 inhibition blocked acute cardiotoxicity when DOX
was delivered at low doses over a 5-week period. The surprising
findingwas that inhibition of p53 activity resulted in greater levels of car-
diomyocyte apoptosis long (3 months) after the termination of DOX
treatment, when compared with DOX-treated NON-TXG mice. p53
inhibition blocked transient P-STAT3[thr705] phosphorylation during
the acute stage, rendering the myocardium more sensitive to DOX-
induced stress (as evidenced by the hyper-induction of acute stage Ku
levels). This increase in DOX-induced stress during drug treatment
Figure 4 Cardiomyocyte-restricted STAT3 deletion exacerbates acute-stage DOX cardiotoxicity. (A) FS in saline- and DOX-treated WT and
STAT3-CKO mice. X-axis indicates the age of the mice at analysis; vertical arrows indicate the age at DOX injection. *P, 0.05 for DOX-treated WT
vs. saline-treated WT mice, †P, 0.05 for DOX-treated WT vs. DOX-treated STAT3-CKO mice, ‡P, 0.05 for DOX-treated STAT3-CKO vs. saline-
treated STAT3-CKO mice. (B) Representative short-axis echocardiograms from saline- and DOX-treatedWT and STAT3-CKO mice. (C) Quantitation
of activatedcaspase-3 immune reactivecardiomyocytes (CSP+CM)permm2 inhearts fromsaline- andDOX-treatedNON-TXGandSTAT3-CKOmice in
the acute stage.
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was associated with a greater rate of cardiomyocyte dropout during the
late stage, and progressive late-stage cardiac dysfunction. Collectively,
these data suggest an explanation as to how p53 inhibition can result
in cardioprotection during drug treatment and, paradoxically, cardio-
toxicity long after the cessation of drug treatment.
STAT3 has previously been implicated in modulating DOX-induced
cardiotoxicity in high-dose/short-duration studies. For example, trans-
genic mice overexpressing STAT3 in cardiomyocytes exhibited
enhanced survival,39 whereas STAT3-CKO mice exhibited reduced
cardiac function (Figure 4),22 when compared with their respective
DOX-treated controls. Moreover, numerous studies have shown a cor-
relation between STAT3 activation and detoxification of reactive
oxygen species.40–44 The transient induction of P-STAT3[thr705]
levels during the acute stage in NON-TXG mice, but not MHC-CB7
mice, makes it a prime candidate for the proposed p53-dependent car-
dioprotective activity. Although P-STAT3[ser727] is also present in the
heart, the absence of dynamic regulation during DOX treatment indi-
cates that changes in phosphorylation at this residue are not responsible
for the p53-dependent cardioprotective activity proposed here. Given
the observation that phospho-mimetic mutants at this residue can
impact cardiomyocyte survival,35 the combined loss P-STAT[thr705]
and P-STAT3[ser727] in STAT3-CKOmice readily explains the relative
decrease in cardiac function and increase in cardiomyocyte apoptosis
following DOX treatment, when compared with DOX-treated WT
mice.
Themechanistic link between the induction of p53 activity and the ac-
tivation of STAT3 is presently not clear. Although the absence of previ-
ousworkdescribing a link betweenp53 induction and JAK (the canonical
upstream regulator of STAT3) pathway activation argues against direct
activation, one cannot rule out the possibility that, as of yet, an uniden-
tified p53-dependent protein kinase mediates P-STAT3[tyr705] phos-
phorylation during DOX treatment. It is also possible that the
activation occurs via an indirect mechanism. For example, it has previ-
ously been shown using a high-dose/short-duration model that DOX
treatment resulted in cardiac atrophy via a p53-dependent mechanism,
and that expression of the MHC-CB7 transgene effectively blocked
DOX-mediated atrophy.45 Inhibition of p53 activity also blocked
DOX-induced cardiac atrophy during acute-stage cardiotoxicity in the
Figure5 Westernblot analysis of protein expression in saline- andDOX-treatedWTandSTAT3-CKOmice.Densitometric quantitationof thewestern
blot signals is also shown.
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current study (see Supplementary material online, Table S2). In other
studies, atrophic cardiac remodelling following heterotopic heart trans-
plantation resulted in STAT3 activation.46 Thus, the absence of STAT3
activation in the MHC-CB7 mice may result from the absence of DOX-
induced cardiac atrophy. It should be noted that enforced expression of
p53 inhibited STAT3 phosphorylation in prostate cancer cell lines,47 in-
dicating that STAT3 can be negatively regulated by p53. On the other
hand, both p53 induction48 and STAT3 activation49 are observed
during autophagy, leading to the suggestion that the pathways function
in parallel to regulate increased autophagic activity.50 Thus, the impact
of p53 on STAT3 activity is dependent upon both the cell type and the
physiological pathway under analysis.
In the absence of STAT3 activation (due to inhibition of p53 in the
MHC-CB7 mice or lineage-specific gene deletion in the STAT3-CKO
mice), a hyper-induction of Ku70 and 80 was observed following
DOX treatment. The absence of increased apoptosis during the acute
stage inMHC-CB7mice argues that Ku expression is not simply tracking
cardiomyocyte death. Additionally, the absence of Ku expression in
saline-treated MHC-CB7 hearts indicates that transgene expression
per se is not responsible for its induction. It is also unlikely that Ku is a
downstream effector of STAT3, as both Ku70 and Ku80 were hyper-
induced in DOX-treated STAT3-CKO mice. Although Ku70 has been
reported toencode anti-apoptotic activity (bybindingBAXandblocking
its translocation to the mitochondria),51 this likely is not the case in the
results presented here given the elevated late-stage cardiomyocyte
apoptosis seen inMHC-CB7mice. Rather, it is more likely that the accu-
mulation of Ku reflects the relative level of myocardial stress (given its
role as a transcription co-factor) and/or the relative level of DNA
damage (given its role in DNA repair) following DOX treatment.
As mentioned above, cardiomyocyte-restricted deletion of
Topoisomerase-II b (Top2b) reduced DOX-induced cardiotoxicity in
mice by blocking DNA damaged-induced p53 activation.11 This work
is noteworthy in that it suggested that reactive oxygen species gener-
ation was secondary to a p53-mediated reduction of the transcription
of genes required for mitochondrial biosynthesis and oxidative
phosphorylation (leading to a concomitant decrease in mitochondrial
function). However, since expression of the CB7 protein blocks
p53-mediated transcriptional activity,21 this mechanism cannot underlie
the late-stage cardiotoxicity observed in the MHC-CB7 mice in the
current study.
In summary, the data presented here indicate that p53 inhibition is
beneficial during acute-stage DOX cardiotoxicity, but detrimental
during late-stage cardiotoxicity. Furthermore, the data suggest a
workingmodel that could explain in part how changes in protein activity
during drug treatment in the acute stage can result in more severe
cardiotoxicity long after the termination of drug treatment. Direct
proof of the proposed mechanism will require the generation of add-
itional transgenic animals with the conditional expression of the rele-
vant proteins (as for example conditional expression of the CB7
protein during the acute stage only, and/or conditional expression of a
constitutively active STAT3 during the acute stage in MHC-CB7 mice).
Nonetheless, the data presented indicate that interventions to ame-
liorate DOX cardiotoxicity could have a rather unexpected negative
impact. These results further underscore the complex nature of anthra-
cycline cardiotoxicity.
Supplementary material
Supplementary Material is available at Cardiovascular Research online.
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